ALLERGY & IMMUNOLOGY INFORMATION CENTER
The approval of the expanded age range was based on data from a clinical trial which evaluated the efficacy of Gardasil (quadrivalent human papillomavirus recombinant vaccine) in 3253 women 27-45 years of age with a median duration of follow-up of 3.5 years post-dose 3.
14 million need to receive two doses of vaccine to reach goal of 80% vaccination by 2026.
Wide variations in influenza vaccine coverage have been noted across healthcare personnel based on occupation and worksite.
Even if the flu shot "misses," as it did last year, it remains one of the best tools we have to help our patients live healthier lives.
Clinicians should inform parents about the safety of vaccines to encourage them to vaccinate their children.
Common reasons that parents give when declining human papillomavirus vaccine for their children are, "My teen is not sexually active," or "Maybe we'll wait until he/she is a bit older." This thinking negates the vaccine's preventive purpose.
With the advent of platform manufacturing technology, vaccines can be developed quickly to stop the spread of outbreaks.
NIH's National Institute of Allergy and Infectious Diseases is researching ways to develop a universal influenza vaccine against multiple strains.